Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

← catalyst calendar

NCT05991323 · readout in 34 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.

Phase
Status
Active, not recruiting
Study type
Observational
Enrollment
100estimated
Sites
49
Countries
Canada, China, France +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-12-12actualWhen the study began enrolling
Primary completion2026-09-22estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-09-22estimatedThe whole study's end, after follow-up
First posted2023-08-14actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-09-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Prurigo Nodularis

Intervention

  • Drug: Dupilumab — also filed as DUPIXENT, SAR231893

Primary outcomes

what the primary-completion date above is the date OF
Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment
measured At baseline
Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment
measured From baseline up to month 18
Proportion of patients who discontinued dupilumab
measured From baseline up to month 18
Frequency of reasons for dupilumab treatment discontinuation
measured From baseline up to month 18
Proportion of patients hospitalized due to PN
measured From baseline up to month 18

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed